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Abstract
Haemangiopericytomas are rare tumours, commonly
mistaken as meningiomas on radiology. These tumours are
considered malignant and treatment involves aggressive
surgery, followed by adjuvant radiation therapy, and close
radiological and clinical follow ups. Herein the authors have
reviewed the recent literature on the management of these
tumours. 
Keywords: Brain tumours, radiation therapy, dural based
tumours 
Introduction
Haemangiopericytomas (HPC) are extremely rare, dural
based malignant tumours, comprising of only 0.4% of all
intracranial neoplasms.1 These tumours originate from
transformation of pericytes located in capillaries and post
capillary venules, and are mostly supratentorial.1 They
commonly arise in individuals in their fourth and fifth
decade of life, and unlike meningiomas, have a slight male
predominance.2,3
HPC are biologically aggressive, and recurrence following
treatment is particularly common, with 5‐year local
recurrence and metastasis rates in the range of 65% and
33%, respectively.4 The mean overall survival for HPC has
been reported to be as low as 7 years after diagnosis.5 The
relatively poor prognosis associated with intracranial HPC
has led several investigators to advocate for aggressive
treatment combining radical surgical resection with
adjuvant radiotherapy. Gamma knife radiosurgery has also
been tried for the treatment of small HPC and has been
found promising in controlling local tumour growth. 
Review of evidence
Extent of resection: Surgical resection has always been the
mainstay in the treatment of haemangiopericytoma. In a
case series of 40 patients published by Rutkowski et al.,
patients with gross total resection (GTR) had better overall
survival compared to those receiving subtotal resection
(STR), regardless of adjuvant radiation.6 (Figures 1 and 2).
The median survival was 18.8 years for patients receiving
GTR compared with 8.75 years for patients receiving STR,
with adjuvant radiation.6 In another study by Kim et al., the
median time for local recurrence of patients subjected to
GTR was 68.3 months; whereas progression free survival
with STR was 37.1 months, and biopsy was 3.5 months.7
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Figure-1:  MRI brain T1-post contrast image sagittal section of a 44 years old male
patient, showing a homogenously enhancing, dural based lesion in the
right middle cranial fossa. It is displacing the adjacent temporal and
frontal lobes, and there is significant peri-lesional oedema. The lesion
was surgically resected and histopathology of this lesion was reported
as meningeal haemangiopericytoma grade III.
Figure-2:  MRI brain FLAIR image sagittal section of the same patient showing 
significant peri-lesional oedema extending to the frontal, temporal and
parietal lobes. Such a finding in dural based 
lesions otherwise suspected to be meningiomas, should raise the 
suspicion of HPC. 
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In a large case series of 523 patients with HPC, surgery was
performed in 86% of the cases, in which 56.9% patients
underwent GTR and 38.6% patients had STR. The results
demonstrated significantly better survival in patients with
GTR compared to STR (157.97 months vs. 110.75 months).8
The 5‐year local control rate for patients with GTR and STR
were 84% and 38%, respectively, according to another
study by Soyuer et al.9
Adjuvant radiation therapy: Several studies have supported
the use of adjuvant radiation therapy for HPC. This may be
in the form of conventional radiation, external beam
radiotherapy or stereotactic radiosurgery. According to
Soyuer et al., none of the 3 patients who received GTR and
adjuvant radiation experienced local disease recurrence,
whereas 5 (45%) of the 11 patients who underwent GTR
without radiation experienced local recurrence.9 Guthrie et
al., also reported significantly better results with adjuvant
radiation.4 In the study, 9 of 17 irradiated tumours recurred
at an average of 75 months after surgery, whereas 13 of 15
nonirradiated tumours recurred at an average of 34 months
after surgery. Although the difference was not statistically
significant, adjuvant radiation improved survival from 62
months to 92 months.4 DuFour et al., also found that
adjuvant radiation provided benefit with regards to local
disease recurrence.10 In their series, recurrence rates for
patients treated with surgery and adjuvant radiation, and
patients treated with surgery alone were 12% and 88%,
respectively.10
Management of recurrent intracranial
haemangiopericytomas with radiosurgery has also been
reported as an effective treatment option. Sheehan et al.,
reviewed a series of 14 patients with 15 recurrent HPC
treated with radiosurgery.11 On follow‐up imaging, 12 of
the 15 tumours had regressed, although 3 had grown,
giving an 80% local control rate.11 In another series by
Chang et al., 6 of the 8 patients treated with radiosurgery
achieved a reduction in size and local control was achieved
in 75% of the cases.12 However, none of the studies were
able to demonstrate an improvement in overall survival of
patients receiving adjuvant radiation in any form. 
Conclusion
Gross total resection of intracranial HPC seems to offer the
best outcome. In cases with residual tumours, adjuvant
radiation therapy is recommended. HPC have a high risk of
recurrence despite these treatment options.
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